Quince Therapeutics, Inc
Quince Therapeutics, Inc. is a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases. Their Phase 3 lead asset, eDSP, for the treatment of the rare pediatric neurodegenerative disease Ataxia-Telangiectasia (A-T) is the first product in development that leverages their proprietary Autologous Intracellular Drug Encapsulation, or AIDE, technology platform, which is a novel drug/device combination that uses an automated encaps